Analysis
EMA must improve the quality of its clinical trial reports
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2291 (Published 25 May 2011) Cite this as: BMJ 2011;342:d2291
Related articles
- Research Methods & Reporting Published: 24 March 2010; BMJ 340 doi:10.1136/bmj.c332
- Analysis Published: 30 March 2010; BMJ 340 doi:10.1136/bmj.c1578
- Research Published: 07 September 2009; BMJ 339 doi:10.1136/bmj.b3244
- Analysis Published: 06 September 2011; BMJ 343 doi:10.1136/bmj.d4849
- Research Published: 26 February 2015; BMJ 350 doi:10.1136/bmj.h796
- Research Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5221
See more
- Chronic insomnia: diagnosis and non-pharmacological managementBMJ November 16, 2016, 355 i5819; DOI: https://doi.org/10.1136/bmj.i5819
- Risks of duloxetine for stress incontinence outweigh benefits, say researchersBMJ November 15, 2016, 355 i6103; DOI: https://doi.org/10.1136/bmj.i6103
- Manufacturers tell FDA why they should be able to promote drugs and devices off labelBMJ November 14, 2016, 355 i6098; DOI: https://doi.org/10.1136/bmj.i6098
- Dietitians have important role in mental health team, say researchersBMJ November 03, 2016, 355 i5913; DOI: https://doi.org/10.1136/bmj.i5913
- Daylight saving is linked to depression, Danish study findsBMJ November 01, 2016, 355 i5857; DOI: https://doi.org/10.1136/bmj.i5857
Cited by...
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
- Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
- Optimizing investigator-led oncology research in Europe
- Agomelatine and the brave old world of narrative-based medicine
- Evidence of comparative efficacy should have a formal role in European drug approvals
- EMA's response to articles
- EMA urgently needs a cure